Soleil Boughton Sells 268,932 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 268,932 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.41, for a total value of $47,738.99.

Hims & Hers Health Trading Up 2.6 %

HIMS stock traded up $0.71 during mid-day trading on Tuesday, reaching $27.61. The company's stock had a trading volume of 10,914,906 shares, compared to its average volume of 9,194,688. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 62.75 and a beta of 1.31. Hims & Hers Health, Inc. has a 12 month low of $8.14 and a 12 month high of $35.02. The business's 50 day moving average price is $26.73 and its 200 day moving average price is $21.53.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health's revenue was up 77.1% compared to the same quarter last year. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of research reports. Needham & Company LLC upped their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a report on Monday. TD Cowen reissued a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Finally, BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday. They set a "buy" rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $24.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock worth $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. State Street Corp increased its position in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock valued at $30,714,000 after purchasing an additional 218,566 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.